Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction

International Journal of Cardiology

Volumn 169, Issue 3, 2013, Pages 177-182

  Carrasco Sánchez, Francisco Javier ^a   Aramburu Bodas, Oscar ^b   Salamanca Bautista, Prado ^b   Morales Rull, José Luis ^c   Galisteo Almeda, Luis ^a   Páez Rubio, María Inmaculada ^a   Arias Jiménez, José Luis ^b   Aguayo Canela, Mariano ^a   Pérez Calvo, Juan Ignacio ^d  

^a HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Galectin 3; Heart failure; Preserved ejection fraction; Prognosis; Reclassification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; GALECTIN 3; UREA;

AGE; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CODING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SODIUM BLOOD LEVEL; UREA BLOOD LEVEL;

GALECTIN-3; HEART FAILURE; PRESERVED EJECTION FRACTION; PROGNOSIS; RECLASSIFICATION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROSPECTIVE STUDIES; STROKE VOLUME;

EID: 84887625229     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.081     Document Type: Article

References (29)

1. I. Gotsman, D. Zwas, C. Lotan, and A. Keren Heart failure and preserved left ventricular function: long term clinical outcome PLoS One 7 2012 e41022
2. J.J. McMurray, S. Adamopoulos, and S.D. Anker ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
3. N.C. Henderson, A.C. Mackinnon, and S.L. Farnworth Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis Am J Pathol 172 2008 288 298
4. N.C. Henderson, A.C. Mackinnon, and S.L. Farnworth Galectin-3 regulates myofibroblast activation and hepatic fibrosis Proc Natl Acad Sci U S A 103 2006 5060 5065
5. R.A. de Boer, A.A. Voors, P. Muntendam, W.H. van Gilst, and D.J. van Veldhuisen Galectin-3: a novel mediator of heart failure development and progression Eur J Heart Fail 11 2009 811 817
6. R.R. Van Kimmenade, J.L. Januzzi Jr., and P.T. Ellinor Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 2006 1217 1224
7. D.J. Lok, P. Van Der Meer, and P.W. de la Porte Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the deal-hf study Clin Res Cardiol 99 2010 323 328
8. R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, R.R. van Kimmenade, and J.L. Januzzi Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 2010 826 832
9. G.M. Felker, M. Fiuzat, and L.K. Shaw Galectin-3 in ambulatory patients with heart failure: results from the hf-action study Circ Heart Fail 5 2012 72 78
10. R.A. de Boer, D.J. Lok, and T. Jaarsma Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
11. J.E. Ho, C. Liu, and A. Lyass Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 2012 1249 1256
12. L. Gullestad, T. Ueland, and J. Kjekshus Galectin-3 predicts response to statin therapy in the controlled rosuvastatin multinational trial in heart failure (corona) Eur Heart J 33 2012 2290 2296
13. R.A. de Boer, F. Edelmann, A. Cohen-Solal, M.A. Mamas, A. Maisel, and B. Pieske Galectin-3 in heart failure with preserved ejection fraction Eur J Heart Fail 15 10 2013 1095 1101
14. T.D. Smilde, D.J. van Veldhuisen, G. Navis, A.A. Voors, and H.L. Hillege Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction Circulation 114 2006 1572 1580
15. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the roc curve to reclassification and beyond Stat Med 27 2008 157 172 [discussion 207-12]
16. N.R. Cook Statistical evaluation of prognostic versus diagnostic models: beyond the roc curve Clin Chem 54 2008 17 23
17. I.S. Anand, T.S. Rector, M. Kuskowski, A. Adourian, P. Muntendam, and J.N. Cohn Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the val-heft Eur J Heart Fail 15 2013 511 518
18. R.A. de Boer, D.J. van Veldhuisen, and R.T. Gansevoort The fibrosis marker galectin-3 and outcome in the general population J Intern Med 272 2012 55 64
19. G.L. Smith, J.H. Lichtman, and M.B. Bracken Renal impairment and outcomes in heart failure: systematic review and meta-analysis J Am Coll Cardiol 47 2006 1987 1996
20. K. Damman, G. Navis, and A.A. Voors Worsening renal function and prognosis in heart failure: systematic review and meta-analysis J Card Fail 13 2007 599 608
21. W.H. Tang, K. Shrestha, and Z. Shao Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival Am J Cardiol 108 2011 385 390
22. D.M. Gopal, M. Kommineni, and N. Ayalon Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure J Am Heart Assoc 1 2012 e000760
23. G.J. Fermann, C.J. Lindsell, and A.B. Storrow Galectin 3 complements bnp in risk stratification in acute heart failure Biomarkers 17 2012 706 713
24. A.R. van der Velde, L. Gullestad, and T. Ueland Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from corona and coach Circ Heart Fail 6 2013 219 226
25. L. Yu, W.P. Ruifrok, and M. Meissner Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis Circ Heart Fail 6 2013 107 117
26. N. Sherwi, S. Merali, and K. Wong Personalizing biomarker strategies in heart failure with galectin-3 Future Cardiol 8 2012 885 894
27. F. Edelmann, A.G. Schmidt, and G. Gelbrich Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (aldo-dhf) Eur J Heart Fail 12 2010 874 882
28. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
29. F.J. Carrasco Sanchez Galectin-3-independent prognosis in heart failure Clin Res Cardiol 100 2011 183